Clinical trials: Resectable Pancreatic Cancer
Resectable Pancreatic Cancer
Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer
This is a window-of-opportunity study that examines the efficacy of doxycycline, and FDA-approved oral antibiotic, on metakaryotic (cancer stem cells) in resectable pancreatic cancer following eight weeks of treatment.
- Trial name
- NCT02775695
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical College of Wisconsin
Resectable Pancreatic Ductal Adenocarcinoma
A Phase II Study of Neoadjuvant FOLFIRINOX
The primary objective of this study is to evaluate the rate of pathologic complete response to neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer using a tissue collection component.
- Trial name
- NCT02178709
- Testing
- FOLFIRINOX
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Indiana University
Pancreatic Cancer
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
A standard treatment for pancreatic cancer is radiation therapy plus chemotherapy after surgery. Radiation therapy and chemotherapy are commonly given for up to six weeks.
- Trial name
- NCT00438256
- Testing
- Proton Beam Radiation, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Cancer
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
1.1 Primary Objective To evaluate the effects of short course preoperative erlotinib treatment in a panel of predictive biomarkers from a group of patients who undergo resection of pancreatic adenocarcinoma with curative intent.
- Trial name
- NCT00841035
- Testing
- erlotinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Alabama at Birmingham
Pancreatic Cancer
Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body
The purpose of this study is to test the safety of focused radiation (Stereotactic Body Radiation Therapy, SBRT) on patients with pancreatic cancer that will be removed surgically.
- Trial name
- NCT02208024
- Testing
- Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Cincinnati
Pancreatic Cancer, Cancer of the Pancreas
Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.
- Conditions
- Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer
- Trial name
- NCT04536077
- Testing
- CDX-301, CDX-1140, Research blood draw
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer Non-resectable
Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer
This study wants to find out how safe and effective the use of Folfirinox combined with Stereotactic Body Radiation Therapy )(SBRT) is for the treatment of pancreatic cancer.
- Trial name
- BCC-RAD-13 (NCT02128100)
- Testing
- Folfirinox, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Louisville
Pancreatic Cancer, Pancreas Cancer
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma
- Trial name
- AA NABPLAGEM (NCT03410030)
- Testing
- High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- HonorHealth Research Institute
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1…
- Trial name
- NCT03727880
- Testing
- Pembrolizumab, Defactinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lei Zheng
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
- Conditions
- Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04669197
- Testing
- Paclitaxel protein bound, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- HonorHealth Research Institute
Pancreatic Cancer
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
The investigators hypothesize that the combination of the FOLFIRINOX regimen (a combination of 5-fluorouracil, irinotecan and oxaliplatin chemotherapy) to provide maximal systemic disease control and FDR-gemcitabine chemotherapy…
- Trial name
- NCT01661088
- Testing
- FOLFIRINOX, Intensity-modulated radiotherapy (IMRT), Surgical Exploration
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Colorectal Cancer, Pancreatic Cancer
High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
This is a multicenter, single arm, 3-cohort, open-label trial of high dose Vitamin C intravenous infusion in subjects with solid tumor malignancies who are eligible for resection (cohort A) or with extended RAS (e.g.KRAS or NRAS)…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT03146962
- Testing
- Vitamin C
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Weill Medical College of Cornell University
Pancreas Neoplasm Malignant Resectable
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.
- Trial name
- NCT02243358
- Testing
- Folfox6, Gemcitabine, Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Henry Ford Health System
Pancreatic Cancer
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
The main purpose of this study is to look at the potential effects of paricalcitol (a drug similar to vitamin D) and nivolumab on pancreatic tumors in patients who are treated with gemcitabine and abraxane.
- Trial name
- NCT03519308
- Testing
- Nivolumab, Nab-Paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pancreatic Cancer
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
The goal of this clinical research study is to learn if a chemotherapy combination called modified Folfirinox (or mFolfirinox), followed by a combination of gemcitabine and radiation therapy, followed by surgery, can help to…
- Trial name
- NCT01560949
- Testing
- Oxaliplatin, Irinotecan, 5-FU
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Neoplasms, Digestive System Neoplasms
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared…
- Conditions
- Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- apact (NCT01964430)
- Testing
- nab-Paclitaxel, Gemcitabine
- Where
- 341 sites in United States, Australia and 19 more
- Volunteers
- 866 people
- Sponsor
- Celgene
Pancreatic Cancer
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation…
- Trial name
- NCT03161379
- Testing
- Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery work in treating patients with pancreatic cancer that can be removed by surgery.
- Trial name
- NCT02427841
- Testing
- Fluorouracil, Gemcitabine, Image Guided Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Carcinoma Non-resectable, Metastatic Pancreatic Cancer
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
People with pancreatic cancer usually have a large amount of the cancer in the area of the pancreas and around it when they are diagnosed with it.
- Trial name
- NCT00761345
- Testing
- gemcitabine, Erlotinib, low dose fractionated radiotherapy
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Cancer
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Surgical resection is the only potentially curative treatment for patients with pancreatic cancer. Patients with BRPC have tumors in close contact with the vasculature but not to the extent that resection is prohibited.
- Trial name
- NCT03099265
- Testing
- neoadjuvant mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Yale University